In 2020, investors are looking for cannabis stocks that can deliver excellent returns following a disappointing 2019, which saw many pot stocks crash to multiyear lows. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) stands out as a promising cannabis stock to own in 2020.
About OWC Pharmaceutical Research
The cannabis stock universe is vast, so for investors who may have just come across OWC Pharmaceutical for the first time an introduction of the company is in order.
OWC Pharmaceutical is an Israel-based cannabis research company. It is focused on research and development of cannabis-based medical products. The company’s work currently includes development of cannabis-based treatments for a variety of diseases and disorders such as multiple myeloma, psoriasis and fibromyalgia.
Moreover, OWC Pharmaceutical provides consulting services to both government and private entities in the field of medical cannabis programs.
OWC Pharmaceutical Research exited 2019 on a high note
While 2019 ended up being one of the toughest year for cannabis stocks, OWC Pharmaceutical had strong finish to the year. The stock gained 35% on December 31. Before that, the stock rose 65% on December 30. The back-to-back gains in the final days of 2019 helped OWC Pharmaceutical cut its losses for the year but also signaled improving investor sentiment on the stock heading into the new year.
OWC Pharmaceutical finished 2019 at $0.089, having pulled from a low of $0.0045 at the beginning of December.
What investors should note is that OWC Pharmaceutical is actually in the early stage of what is shaping up to be a powerful breakout, and so still there is a long runaway ahead.
Medical cannabis market presents huge revenue opportunity for OWC Pharmaceutical Research
OWC Pharmaceutical’s focus on development of cannabis-based treatments gives it an exposure to a huge revenue opportunity. The medical cannabis market is growing by leaps and bounds. The global medical cannabis market generated $11.8 billion in revenue in 2017, according to Zion Market Research estimates. The market is on course to grow to $40.9 billion in annual revenue by 2024.
OWC Pharmaceutical stands to benefit from the rapidly burgeoning global medical cannabis market with its clinically validated and patent protected cannabis-based treatments for some of the most troubling medical conditions.
Recent major developments at OWC Pharmaceutical Research
There have been several notable developments in recent months at OWC Pharmaceutical that could benefit the stock down the road. Here are some of those key developments:
OWC Pharmaceutical Research patent application accepted in the United States
OWC Pharmaceutical announced last month that the United States Patent and Trademark Office accepted its patent application for cannabis-based topical formulations for use skin conditions.
The cannabis extract formulation that OWC Pharmaceutical has sought patent protection for in the United States could offer relief to people suffering from skin conditions such as Psoriatic lesions of the face. Currently, this skin condition lacks an effective alternative topical remedy, which is why success in this area promises great rewards for OWC Pharmaceutical down the road.
OWC Pharmaceutical has already secured patents for its cannabis formulations for skin disorders in Australia and the Czech Republic. Now the company is on course for a significant boost to its intellectual property portfolio with a US patent for the formulations.
OWC Pharmaceutical Research partners with STENOCARE to develop cannabis medical products
In November, OWC Pharmaceutical teamed up with STENOCARE on a program to develop and commercialize cannabis-based medical products for a variety of conditions. The first product from the partnership is expected to launch in 2021 or 2022. That product will initially be sold in STENOCARE’s existing markets in Denmark and Ireland.
STENOCARE is a Danish company focused on cultivation, production, and supply of medical cannabis products for the global market. It will provide the raw materials that the partnership will work on to develop new cannabis treatments for specific conditions.
“STENOCARE is a strong match for OWC with its unique focus on pharma-grade production and distribution of medical cannabis in interesting markets. This is fully aligned with OWC’s approach to develop and commercialize products for millions of patients,” commented OWC Pharmaceutical CEO Mordechai Bignitz.
Considering OWC Pharmaceutical’s 2017 high just over $3, the stock has the potential to return 2600% from its current price. Therefore, taking into account OWC Pharmaceutical’s strong fundamentals as well, the stock stands out as an attractive comeback play in 2020.
We will be updating our subscribers as soon as we know more. For the latest updates on OWC Pharmaceutical Research, sign up below!
Disclosure: We have no position in OWC Pharmaceutical Research and have not been compensated for this article.
Forget APHA and ACB, Buy GTBIF and TCNNF
There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).
On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.
There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.
Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.
The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…